Dr. Elizabeth K. Lee discusses the RAINFOL-01 clinical trial evaluating treatment with Rina-S in advanced ovarian cancer.

Discover AbbVie's strong performance, with immunology growth and undervaluation despite challenges. Click here to read an ...

Epsilogen has acquired antibody developer TigaTx in a deal that collates work from the companies’ alternative antibody ...

What should investors do when stocks are tanking over the short term? Three Motley Fool contributors think they've found ...

ImmunoGen, Inc. has announced that its platinum-resistant ovarian cancer drug ELAHERE (mirvetuximab soravtansine-gynx) has been granted FDA accelerated approval. This first FDA antibody-drug ...

AbbVie's Elahere has been shown to reduce the risk of death in patients with folate receptor-alpha (FRα) positive, platinum-resistant ovarian cancer by a third, reinforcing its blockbuster ...

The European Commission (EC) has granted marketing authorisation to AbbVie’s Elahere (mirvetuximab soravtansine) for the treatment of folate receptor-alpha (FRα) platinum-resistant ovarian ...

AstraZeneca has been busy in recent years pumping up its oncology pipeline via a shopping list of assets and companies. | ...

The American multinational pharmaceutical company has strengthened its portfolio in recent years through several key acquisitions, adding significant growth assets such as the cancer drug Elahere ...